

ABOUT THE TEST FoundationOne®Liquid is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating tumor DNA.

PATIENT

DISEASE Breast cancer (NOS)
 NAME Not Given
 DATE OF BIRTH Not Given
 SEX Not Given
 MEDICAL RECORD # Not Given

PHYSICIAN

ORDERING PHYSICIAN Not Given
 MEDICAL FACILITY Not Given
 ADDITIONAL RECIPIENT Not Given
 MEDICAL FACILITY ID Not Given
 PATHOLOGIST Not Given

SPECIMEN

SPECIMEN ID Not Given
 SPECIMEN TYPE Blood
 DATE OF COLLECTION Not Given
 SPECIMEN RECEIVED Not Given

Biomarker Findings

MSI Status Undetermined

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

ESR1 D538G, E380Q, Y537N
FGFR1 amplification
NF1 G751fs*9
MDM2 amplification
MYC amplification
TP53 R248Q

6 Therapies with Clinical Benefit
 3 Therapies with Lack of Response

30 Clinical Trials

BIOMARKER FINDINGS
ACTIONABILITY
MSI Status Undetermined

GENOMIC FINDINGS	MAF %	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
ESR1 - D538G	3.0%	Fulvestrant	none
	E380Q	0.09%	▲ Anastrozole ¹
	Y537N	0.3%	▲ Exemestane ¹
9 Trials see p. 12		▲ Letrozole ¹	
FGFR1 - amplification	n/a	none	Pazopanib
	6 Trials see p. 14		Ponatinib
NF1 - G751fs*9	0.45%	none	Cobimetinib
	9 Trials see p. 15		Trametinib
			Binimetinib
MDM2 - amplification	n/a	none	none
	1 Trials see p. 16		

▲ 1. Patient may be resistant to indicated therapy

CRF# XXXXXXXX

GENOMIC FINDINGS	MAF %	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
MYC - amplification	n/a	none	none
5 Trials see p. 17			

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIALS OPTIONS


For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

TP53 - R248Q p. 5

NOTE Genomic alterations detected may be associated with activity of certain FDA-approved drugs; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type.



CRF# XXXXXXXX



HISTORIC PATIENT FINDINGS		TEST 1
ESR1	● D538G*2	3.0%
	● E380Q	0.09%
	● Y537N	0.3%
FGFR1	amplification	n/a
NF1	● G751fs*9	0.45%
MDM2	amplification	n/a
TP53	amplification	n/a
TP53	● R248Q	21.0%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid or FoundationOne® tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.